Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, data up to January to March 2025
Updated 10 July 2025
Applies to England
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-infographic-mrsa-mssa-and-gram-negative-bacteraemia-and-cdi-data-up-to-january-to-march-2025
Gram-negative bacteraemias (E. coli, Klebsiella spp. and P. aeruginosa)
Pseudomonas aeruginosa (P. aeruginosa) bacteraemia
January to March 2024: 7.3 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
January to March 2025: 6.8 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
Klebsiella species (spp.) bacteraemia
January to March 2024: 22 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
January to March 2025: 22 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
Escherichia coli (E. coli) bacteraemia
January to March 2024: 72 out of every 100,000 persons developed an E. coli bacteraemia.
January to March 2025: 73 out of every 100,000 persons developed an E. coli bacteraemia.
Staphylococcus aureus (S. aureus) MRSA and MSSA bacteraemia and Clostridioides difficile (C. difficile) infections
Meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia
January to March 2024: 1.7 out of every 100,000 persons developed an MRSA bacteraemia.
January to March 2025: 1.8 out of every 100,000 persons developed an MRSA bacteraemia.
Meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia
January to March 2024: 24 out of every 100,000 persons developed an MSSA bacteraemia.
January to March 2025: 24 out of every 100,000 persons developed an MSSA bacteraemia.
Clostridioides difficile (C. difficile) infection
January to March 2024: 30 out of every 100,000 persons developed a C. difficile infection.
January to March 2025: 29 out of every 100,000 persons developed a C. difficile infection.